Last week, readers were most interested in a story about Diasorin's submission to FDA for its POC testing instrument.

Health Canada has allowed the firm to bypass a requirement that tests be authorized for non-professional use prior to self-test authorization.

Investigators compared risk prediction using PathomIQ's platform to molecular test results, evaluating its ability to predict biochemical recurrence in high-risk patients.

The Tulane team has developed a handful of other assays for TB detection, including a mass spec test for paucibacillary TB ...

Broader macroeconomic uncertainty has resulted in continued cautiousness for both investors and acquirers in the in vitro ...

The Glasgow, Scotland-based firm's Panaromic Platform uses an infrared spectroscopy-based test with machine learning-developed algorithms to detect signals of cancer.

A lab owner, marketing firm owner, and doctor have been sentenced to between 13 months and five years in prison for their roles in a multimillion-dollar lab fraud scheme.

NEW YORK – Diasorin said Wednesday that it has submitted a point-of-care molecular testing system, along with a four-target respiratory panel, for US Food and Drug Administration 510 (k) marketing ...

Lund, Sweden-based Qlucore aims to have bladder cancer and AML tests available for clinical use in Europe by 2027.